Last reviewed · How we verify

MACIMORELIN ACETATE — Competitive Intelligence Brief

MACIMORELIN ACETATE (MACIMORELIN ACETATE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth Hormone Secretagogue Receptor Agonist [EPC].

marketed Growth Hormone Secretagogue Receptor Agonist [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

MACIMORELIN ACETATE (MACIMORELIN ACETATE).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MACIMORELIN ACETATE TARGET MACIMORELIN ACETATE marketed Growth Hormone Secretagogue Receptor Agonist [EPC] 2017-01-01
Macrilen MACIMORELIN Aeterna Zentaris marketed Growth Hormone Secretagogue Receptor Agonist Growth hormone secretagogue receptor type 1 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth Hormone Secretagogue Receptor Agonist [EPC] class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MACIMORELIN ACETATE — Competitive Intelligence Brief. https://druglandscape.com/ci/macimorelin-acetate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: